Riekje Winzer

Riekje Winzer

Auto-generated profile, based on publicly available information

Riekje Winzer

Department of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ESEnja Schneider
Enja Schneider
RWRiekje Winzer
Riekje Winzer
ARAnne Rissiek
Anne Rissiek
IRIsabell Ricklefs
Isabell Ricklefs
CMCatherine Meyer-Schwesinger
Catherine Meyer-Schwesinger
ETEva Tolosa
Eva Tolosa
Immune cells at sites of inflammation are continuously activated by local antigens and cytokines, and regulatory mechanisms must be enacted to control inflammation. The stepwise hydrolysis of extracellular ATP by ectonucleotidases CD39 and CD73 generates adenosine, a potent immune suppressor. Here we report that human effector CD8 T cells contribute to adenosine production by releasing CD73-containing extracellular vesicles upon activation. These extracellular vesicles have AMPase activity, and the resulting adenosine mediates immune suppression independently of regulatory T cells. In addition, we show that extracellular vesicles isolated from the synovial fluid of patients with juvenile idiopathic arthritis contribute to T cell suppression in a CD73-dependent manner. Our results suggest that the generation of adenosine upon T cell activation is an intrinsic mechanism of human effector T cells that complements regulatory T cell-mediated suppression in the inflamed tissue. Finally, our data underscore the role of immune cell-derived extracellular vesicles in the control of immune responses.

Verified
Journal Article
Open access
PDF file
NBNiklas Bach
Niklas Bach
RWRiekje Winzer
Riekje Winzer
ETEva Tolosa
Eva Tolosa
Walter FiedlerWalter Fiedler
Walter Fiedler
Franziska BrauneckFranziska Brauneck
Franziska Brauneck
The search for new and effective treatment targets for cancer immunotherapy is an ongoing challenge. Alongside the more established inhibitory immune checkpoints, a novel potential target is CD73. As one of the key enzymes in the purinergic signalling pathway CD73 is responsible for the generation of immune suppressive adenosine. The expression of CD73 is higher in tumours than in the corresponding healthy tissues and associated with a poor prognosis. CD73, mainly by the production of adenosine, is critical in the suppression of an adequate anti-tumour immune response, but also in promoting cancer cell proliferation, tumour growth, angiogenesis, and metastasis. The upregulation of CD73 and generation of adenosine by tumour or tumour-associated immune cells is a common resistance mechanism to many cancer treatments such as chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Therefore, the inhibition of CD73 represents a new and promising approach to increase therapy efficacy. Several CD73 inhibitors have already been developed and successfully demonstrated anti-cancer activity in preclinical studies. Currently, clinical studies evaluate CD73 inhibitors in different therapy combinations and tumour entities. The initial results suggest that inhibiting CD73 could be an effective option to augment anti-cancer immunotherapeutic strategies. This review provides an overview of the rationale behind the CD73 inhibition in different treatment combinations and the role of CD73 as a prognostic marker.

18 August 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
LSLaura Schäkel
Laura Schäkel
SMSalahuddin Mirza
Salahuddin Mirza
RWRiekje Winzer
Riekje Winzer
VLVittoria Lopez
Vittoria Lopez
RIRiham Idris
Riham Idris
CMChrista Müller
Christa Müller
Background: An important mechanism, by which cancer cells achieve immune escape, is the release of extracellular adenosine into their microenvironment. Adenosine activates adenosine A2A and A2B receptors on immune cells constituting one of the strongest immunosuppressive mediators. In addition, extracellular adenosine promotes angiogenesis, tumor cell proliferation, and metastasis. Cancer cells upregulate ectonucleotidases, most importantly CD39 and CD73, which catalyze the hydrolysis of extracellular ATP to AMP (CD39) and further to adenosine (CD73). Inhibition of CD39 is thus expected to be an effective strategy for the (immuno)therapy of cancer. However, suitable small molecule inhibitors for CD39 are not available. Our aim was to identify drug-like CD39 inhibitors and evaluate them in vitro. Methods: We pursued a repurposing approach by screening a self-compiled collection of approved, mostly ATP-competitive protein kinase inhibitors, on human CD39. The best hit compound was further characterized and evaluated in various orthogonal assays and enzyme preparations, and on human immune and cancer cells. Results: The tyrosine kinase inhibitor ceritinib, a potent anticancer drug used for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer, was found to strongly inhibit CD39 showing selectivity versus other ectonucleotidases. The drug displays a non-competitive, allosteric mechanism of CD39 inhibition exhibiting potency in the low micromolar range, which is independent of substrate (ATP) concentration. We could show that ceritinib inhibits ATP dephosphorylation in peripheral blood mononuclear cells in a dose-dependent manner, resulting in a significant increase in ATP concentrations and preventing adenosine formation from ATP. Importantly, ceritinib (1–10 µM) substantially inhibited ATP hydrolysis in triple negative breast cancer and melanoma cells with high native expression of CD39. Conclusions: CD39 inhibition might contribute to the effects of the powerful anticancer drug ceritinib. Ceritinib is a novel CD39 inhibitor with high metabolic stability and optimized physicochemical properties; according to our knowledge, it is the first brain-permeant CD39 inhibitor. Our discovery will provide the basis (i) to develop more potent and balanced dual CD39/ALK inhibitors, and (ii) to optimize the ceritinib scaffold towards interaction with CD39 to obtain potent and selective drug-like CD39 inhibitors for future in vivo studies.

19 October 2022 in European Journal of Immunology
Verified
Journal Article
Open access
RWRiekje Winzer
Riekje Winzer
ASArnau Serracant‐Prat
Arnau Serracant‐Prat
VBValerie J. Brock
Valerie J. Brock
CPCarolina Pinto‐Espinoza
Carolina Pinto‐Espinoza
BRBjörn Rissiek
Björn Rissiek
ETEva Tolosa
Eva Tolosa
Extracellular ATP activates the P2X7 receptor, leading to inflammasome activation and release of pro‐inflammatory cytokines in monocytes. However, a detailed analysis of P2X7 receptor expression and function in the human T cell compartment has not been reported. Here, we used a P2X7‐specific nanobody to assess cell membrane expression and function of P2X7 on peripheral T lymphocyte subsets. The results show that innate‐like T cells, which effectively react to innate stimuli by secreting high amounts of pro‐inflammatory cytokines, have the highest expression of P2X7 in the human T cell compartment. Using Tγδ cells as example for an innate‐like lymphocyte population, we demonstrate that these cells are more sensitive to P2X7 receptor activation than conventional T cells, affecting fundamental cellular mechanisms like calcium signaling and ATP‐induced cell death. The increased susceptibility of innate‐like T cells to P2X7‐mediated cell death provides a mechanism to control their homeostasis under inflammatory conditions. Understanding the expression and function of P2X7 on human immune cells is essential to assume the benefits and consequences of newly developed P2X7‐based therapeutic approaches.

7 November 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
RWRiekje Winzer
Riekje Winzer
JHJohanna Hiefner
Johanna Hiefner
RHRomy Hackbusch
Romy Hackbusch
MLMoritz A. Link
Moritz A. Link
GTGötz Thomalla
Götz Thomalla
AWAnna Worthmann
Anna Worthmann
Adenosine triphosphate (ATP) and its breakdown products, including adenosine, play key roles in regulating immune responses. Altered ATP and adenosine levels in blood may reflect the presence or development of various pathologies; however, their rapid metabolism and clearance makes accurate measurement of their concentrations difficult. Not surprisingly, studies simultaneously monitoring ATP and its breakdown products are sparse and show conflicting results, and the workflows used are difficult to implement in clinical routine. Here, we present the simultaneous measurement of ATP and its metabolites in blood samples from healthy donors by combining a liquid chromatography-mass spectrometry-based quantification method with various procedures of blood sampling. We find that ATP and adenosine are best preserved in an ethylenediaminetetraacetic acid (EDTA) blood collection tube containing ectonucleotidase and nucleoside transporter inhibitors. In contrast, inosine and its downstream metabolites are detected in a serum collection tube without inhibitors. Therefore, we propose the use of these two sampling tubes to obtain a faithful determination of ATP and its degradation products. Overall, our approach provides a valuable and reliable tool to monitor changes in the concentration of ATP metabolites that can be easily implemented for biobanking purposes in the context of clinical trials.

4 October 2024 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
FGFynn Gerlach
Fynn Gerlach
FMFranziska Möckl
Franziska Möckl
DKDejan Kovacevic
Dejan Kovacevic
VBValerie J. Brock
Valerie J. Brock
RWRiekje Winzer
Riekje Winzer
BDBjörn-Philipp Diercks
Björn-Philipp Diercks
Local, sub-second Ca2+ signals, termed Ca2+ microdomains, are highly dynamic and short-lived Ca2+ signals, which result in a global [Ca2+]i elevation and might already determine the fate of a T cell. Upon T cell receptor activation, NAADP is formed rapidly, binding to NAADP binding proteins (HN1L/JPT2, LSM12) and their respective receptors (RyR1, TPC2) sitting on intracellular Ca2+ stores, like the ER and lysosomes, and leading to subsequent release and elevation of [Ca2+]i. To capture these fast and dynamically occurring Ca2+ signals, we developed a high-resolution imaging technique using a combination of two Ca2+ indicators, Fluo-4 AM and FuraRed AM. For postprocessing, an open-source, semi-automated Ca2+ microdomain detection approach was developed based on the programming language Python. Using this workflow, we are able to reliably detect Ca2+ microdomains on a subcellular level in primary murine and human T cells in high temporal and spatial resolution fluorescence videos. This method can also be applied to other cell types, like NK cells and murine neuronal cell lines.